Relisma Mechanism of Action

Pharmacology: Pharmacodynamics: Salbutamol inhaler is a beta-2-adrenoreceptor agonist; bronchodilator. It is a hydrofluoroalkane (HFA) based environment friendly inhaler. Because it does not contain chlorofluorocarbon (CFC) as propellant which is one of the main reasons of ozone layer depletion. Salbutamol sulphate relaxes the muscles in the walls of small air passages in the lungs. Salbutamol is used in the treatment of asthma and other forms of reversible airways obstruction.
Pharmacokinetics: Absorption: After administration through the inhaled route, between 10% to 20% of the dose reaches the lower airways. The remainder is retained in the delivery system or is deposited in the oropharynx, from where it is swallowed. The fraction deposited in the airways is absorbed into the pulmonary tissues and circulation but is not metabolized by the lung.
Distribution: Salbutamol (as Sulfate) is bound to plasma proteins to the extent of 10%.
Metabolism: The drug is excreted unchanged in the urine.
Elimination: The majority of a dose of salbutamol given intravenously, orally or by inhalation is excreted within 72 hours primarily in the urine.